The
findings
from
the
clinical
study,
conducted
Thai
Binh
University
of
Medicine
and
Pharmacy
in
collaboration
with
other
institutions,
was
published
on
January
27,
2025,
in
Scientific
Reports-Nature,
a
renowned
journal
under
the
Nature
Portfolio
(UK).
The
results
demonstrated
significant
effectiveness
in
children
within
just
3–7
days
of
use.
Additionally,
data
also
showed
positive
improvements
in
adults,
highlighting
the
product’s
potential
for
broader
application
in
the
future.
The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems.
In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline
According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear’s natural defense barrier.
This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX’s efficacy in respiratory care but also affirms Vietnam’s biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children.
Dr.
Nguyen
Hoa
Anh,
Chairman
and
Founder
of
LiveSpo
Pharma,
shared:
“At
LiveSpo,
we
prioritize
the
research
and
development
of
internationally
standardized
products,
combining
modern
medicine
with
advanced
probiotic
technology
to
deliver
safe
and
effective
health
solutions
for
the
community
–
all
with
a
vision
of
A
Future
Without
Antibiotics.”
References:
Khieu
TH,
Le
DP,
Nguyen
BT,
Ngo
BT,
Chu
HT,
Truong
DM,
Nguyen
HM,
Nguyen
AH,
Pham
TD,
Van
Nguyen
AT.
Alleviating
symptoms
of
paediatric
acute
rhinosinusitis
and
acute
otitis
media
with
otorrhea
using
nasal-spraying
Bacillus
probiotics:
a
randomized
controlled
trial.
Sci
Rep.
2025
Jan
27;15(1):3410.
doi:
10.1038/s41598-025-87372-2.
PMID:
39870748;
PMCID:
PMC11772584.
https://livespo.com
Hashtag: #LiveSpo
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate